Table of Contents Author Guidelines Submit a Manuscript
Oxidative Medicine and Cellular Longevity
Volume 2013 (2013), Article ID 609019, 8 pages
Research Article

Mild Systemic Oxidative Stress in the Subclinical Stage of Alzheimer’s Disease

1Instituto de Química, USP, Cidade Universitária, Avenida Lineu Prestes 748, 05508-900 São Paulo, SP, Brazil
2Instituto de Ciências Ambientais, Química e Farmacêuticas, UNIFESP, Rua Arthur Riedel 275, 09972-270 Diadema, SP, Brazil
3Departamento de Hematologia e Oncologia, FMABC, Avenida Príncipe de Gales 821, 09060-650 Santo André, SP, Brazil
4Departamento de Medicina, UNIFESP, Rua Sena Madureira 1500, 04021-001 São Paulo, SP, Brazil
5Departamento de Medicina Preventiva, UNIFESP, Rua Sena Madureira 1500, 04021-001 São Paulo, SP, Brazil

Received 14 July 2013; Accepted 8 November 2013

Academic Editor: Sara Mostafalou

Copyright © 2013 Leandro Giavarotti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Alzheimer’s disease (AD) is a late-onset, progressive degenerative disorder that affects mainly the judgment, emotional stability, and memory domains. AD is the outcome of a complex interaction among several factors which are not fully understood yet; nevertheless, it is clear that oxidative stress and inflammatory pathways are among these factors. 65 elderly subjects (42 cognitively intact and 23 with probable Alzheimer’s disease) were selected for this study. We evaluated erythrocyte activities of superoxide dismutase, catalase, and glutathione peroxidase as well as plasma levels of total glutathione, α-tocopherol, β-carotene, lycopene, and coenzyme Q10. These antioxidant parameters were confronted with plasmatic levels of protein and lipid oxidation products. Additionally, we measured basal expression of monocyte HLA-DR and CD-11b, as well as monocyte production of cytokines IL1-α, IL-6, and TNF-α. AD patients presented lower plasmatic levels of α-tocopherol when compared to control ones and also higher basal monocyte HLA-DR expression associated with higher IL-1α production when stimulated by LPS. These findings support the inflammatory theory of AD and point out that this disease is associated with a higher basal activation of circulating monocytes that may be a result of α-tocopherol stock depletion.

1. Introduction

Alzheimer’s disease (AD) is a neurodegenerative disorder resulting in progressive neuronal death and memory loss [1]. Histopathologically, the disease is characterized by intraneuronal neurofibrillary tangles (NFT) (aggregations of a hyperphosphorylated form of the microtubule-associated protein tau) and extracellular deposits of neuritic plaques composed of amyloid-β(Aβ) protein, a 40–43 amino acid proteolytic fragment derived from the amyloid precursor protein [2].

Although AD is considered a neurodegenerative disease, both inflammation and oxidative stress are present early and throughout its pathogenesis. One of the early clues as to AD as an inflammatory process was the finding that rheumatoid arthritis patients taking high levels of anti-inflammatory drugs had a low incidence of AD [3]. Inflammatory mechanisms may significantly contribute to disease progression and chronicity, with proinflammatory cytokines (notably IL-1α and IL-1β) being found throughout the brain of individuals with AD when analyzed at autopsy [1]. Many neuroinflammatory mediators including complement activators and inhibitors, chemokines, cytokines, reactive species, and inflammatory enzymes are generated and released by microglia, astrocytes, and neurons [4].

However, the precise implications of the inflammatory response for neurodegeneration have not been elucidated. A current hypothesis considers that an extracellular insult to neurons could trigger the production of inflammatory cytokines by astrocytes and microglia. The cytokines, namely, IL-1β, TNF-α, and IL-6, could affect the normal behavior of neuronal cells. Therefore, dysfunction at this core level may lead to abnormalities such as neurofibrillary degeneration in AD [5].

It is well characterized that there is oxidative stress in the AD brain. Lower plasma antioxidant levels and alterations in antioxidant enzyme activities were reported in mild cognitive impairment (MCI) patients and patients at early AD stages, suggesting an imbalance between reactive species production and antioxidant defense systems in the plasma of AD patients. This was substantiated by an increase in DNA, lipid, and protein oxidation products found in blood and cerebrospinal fluid (CSF) obtained from AD patients in comparison with controls [6].

At the same time microglial cells activation is prominent during AD. Microglia are bone marrow-derived cells of the monocyte lineages that, like peripheral tissue macrophages, become phagocytic and produce reactive oxygen species [3]. However, the evaluation of microglia activity during the development of AD in human patients is impossible due to its localization, thus justifying demand for models that use parameters of easy access and reflecting the state of activation of microglia. However, the studies with monocytes could contribute to the understanding of inflammatory component in AD, establishing, at the same time, the possibility of using a minimally invasive technique, such as blood collection.

As exposed, AD has an important component that involves inflammatory reactions associated with reactive species release and lower antioxidant levels. Thus, this paper aims at verifying blood oxidative markers and monocyte inflammatory parameters in elderly subjects who present with very mild cognitive impairment.

2. Methods

2.1. Subjects

Patients participating in this study were part of the last wave of Epidoso Project receiving monitoring on aging by a multidisciplinary team [7].

65 elderly subjects (mean age 82 years) were selected for this study. All patients had their functional capacity and laboratory profile evaluated. These seniors were initially subjected to a clinical survey conducted by a geriatrician, consisting of history taking, physical examination, and evaluation of mental autonomy, through the degree of cognitive function. Patients with a history of cardiovascular disease, cancer, or chronic inflammatory diseases as well as individuals with current inflammatory alterations, assessed by erythrocyte sedimentation rate or plasma levels of C-reactive protein, were not included in this study.

The study protocol was submitted to the Ethics Committee of UNIFESP and was approved under number 0859/03. All patients or their guardians signed informed consent.

2.2. Assessment of Patients’ Cognitive Ability

Minimental state examination was used for screening cognitive deficits among patients [8]. The maximum score is 30 and scores lower than 24 were considered indicative of some kind of cognitive dysfunction.

Patients who scored less than 24 points in MMSE were then tested with CDR (Clinical Dementia Rating) [9, 10].

Patients were considered cognitively intact (INT group; ) when CDR was <1, while others were included in the group of patients with probable Alzheimer’s disease (AD group; ) if CDR was ≥1.

2.3. Measurements of Erythrocytes Parameters

Blood samples from participants were obtained after 12 hours of fasting. Part of whole blood was used for flow cytometry. After plasma separation, erythrocytes were used to measure total glutathione content (TGSH) [11] and the remaining hemolysate to assess the activities of antioxidant enzymes [7], Cu-Zn superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), all adjusted by hemoglobin concentration.

2.4. Measurements of Plasma Parameters

Plasma samples were stored at −80°C for later determination of α-tocopherol, β-carotene, lycopene, coenzyme Q10, and vitamin C [7]. For extraction, 20 μL plasma aliquots were mixed with 100 μL extraction solvent (50% ethanol proanalysis (pa), 50% 1-butanol pa, containing 5 mg butylhydroxytoluene/mL, and 8 μmol Tocol/L as an internal standard) to extract the vitamins and to denature plasma proteins. The sample was then mixed by vortex for 30 s and centrifuged at 21 000 ×g for 10 min at 4°C. The supernatant was transferred to a polypropylene vial. This method uses precolumn and reverse phase C18 column and UV-VIS detector with deuterium lamp, with a mobile phase consisting of 80% acetonitrile, 3% methanol (100 mM ammonium acetate, 0.1% triethylamine), and 15% dioxan. The mobile phase is pumped through the system by a flow of 1.5 mL/min with maximum pressure of 350 Kgf and the minimum of 0. The wavelength was established by the method for each parameter and run time for it was 4 to 6 minutes.

Plasma was also used to determine the concentration of thiobarbituric acid reactive substances (TBARS) [7] and level of oxidized proteins, expressed as plasma carbonyls [12].

2.5. Monocyte Activation Parameters

In order to evaluate basal activation of circulating monocytes, cell surface HLA-DR and CD-11b levels were assessed by flow cytometry, as described elsewhere [13]. Monocytes were identified by monoclonal antibodies anti-CD14-pernidin chlorophyll protein (PerCP); neutrophils were excluded with CD66b-fluorescein isothiocyanate (FITC) labeling. Cell surface molecules were marked with anti-HLA-DR-phycoerythrin (PE) and anti-CD11b-allophycocyanin (APC); controls were incubated with anti-HLA-DR-PE and CD11b-APC isotypes.

Intracellular production of IL-1α, IL-6, and TNF-α was quantified by flow cytometry in monocytes stimulated with LPS and treated with monensin in order to prevent cytokine release [13]. Monocytes were identified by monoclonal antibodies for surface staining (anti-CD66b-FITC and anti-CD14-PerCP) and cytokine production was detected using monoclonal antibodies anti-IL-1α-PE, anti-IL-6-PE, and anti-TNFα-APC or their respective isotype controls.

Data were acquired using a FACSCalibur flow cytometer and CellQuest software (both from BD Immunocytometry Systems).

2.6. Reactive Oxygen Species Assay

Whole blood samples were first stained with anti-CD14 PerCP for monocyte identification; samples were subsequently incubated with 2′,7′-dichlorofluorescein diacetate (DCFH-DA), a stable compound, nonfluorescent, which diffuses into the cells and is hydrolyzed to 2′,7′-dichlorofluorescein (DCFH). Upon cell stimulation with LPS, DCFH was oxidized to DCF by reactive species, mostly H2O2, emitting high levels of green fluorescence, which was detected by flow cytometry [14] using a FACSCalibur flow cytometer and CellQuest software (both from BD Immunocytometry Systems).

2.7. Statistical Analysis

Normality of data distribution was assessed by Shapiro-Wilk test. Comparison between average results of the groups was performed using Student test for independent samples. Correlation analysis between data was performed using Spearman correlation test. All data were processed and analyzed by appropriate statistical tests using SPSS 17 software.

3. Results

No changes were observed on plasma activity of the major erythrocyte antioxidant enzymes SOD, catalase, and glutathione peroxidase (Table 1). Table 1 also shows that total glutathione levels were similar in both cognitively intact (INT) and in group of patients with probable AD.

Table 1: Oxidative stress parameters in erythrocyte (RBC). Antioxidant enzymes: superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx), and total glutathione level (TGSH). INT (cognitively intact patients; ) and AD (patients with probable Alzheimer’s disease; ). Values shown correspond to the means ± SEM. Comparison between average results of the groups was performed using Student’s -test for independent samples.

Lipid peroxidation (measured as TBARS) and plasmatic protein oxidation measured as the amount of circulating protein carbonyls did not significantly differ between the groups INT and AD (Table 2).

Table 2: Oxidative stress parameters in plasma. INT (cognitively intact patients; ) and AD (patients with probable Alzheimer’s disease; ). Values shown correspond to the means ± SEM. Comparison between average results of the groups was performed using Student’s -test for independent samples.

Plasma vitamin C levels were equivalent in both groups, as illustrated in Table 2. Values of circulating α-tocopherol were about 20% lower in patients with probable Alzheimer’s disease compared with cognitively intact patients. This difference was statistically significant. It was observed that the two groups studied had similar plasma levels of β-carotene, lycopene, and coenzyme Q10 (Table 2).

Table 3 shows that Cu, Zn-SOD activity had a positive correlation with catalase and glutathione peroxidase activities, as well as total glutathione content. Catalase activity, in turn, also had positive correlation with glutathione peroxidase activity and total glutathione content in erythrocytes. Glutathione peroxidase activity and total glutathione content in red blood cells also had a significant positive correlation. The same two parameters negatively correlated with lipid peroxidation products in plasma.

Table 3: Correlation between antioxidant erythrocytes parameters and plasmatic oxidation products. Superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx), total glutathione level (TGSH), and thiobarbituric acid reactive substances (TBARS). Analysis was performed using the Spearman correlation test.

Monocytes of patients with probable Alzheimer’s disease expressed approximately 70% more HLA-DR than the cognitively intact patients. On the other hand, there were no differences on the expression of CD11b by monocytes obtained from the two groups (Figure 1 and Table 4).

Table 4: Monocyte activation parameters. INT (cognitively intact patients; ) and AD (patients with probable Alzheimer’s disease; ); GMFI: geometric mean fluorescence intensity; % URQ: percentage of events in the upper right quadrant. Values shown correspond to the means ± SEM. Comparison between average results of the groups was performed using Student test for independent samples.
Figure 1: Representative flow cytometric analysis of whole blood samples stained with anti-CD11b-APC (right column) and anti-HLA-DR-PE (left column) monoclonal antibodies. From all events acquired in gate R1 (upper left graph), CD14-positive monocytes (gate R2, separated from CD66b-positive neutrophils in gate R3; upper right graph) were used for histogram calculation of the geometric mean fluorescence intensity (GMFI). A similar analysis was performed for the detection of fluorescent DCF in the ROS assay (histogram not shown). INT (sample from cognitively intact patient) and AD (sample from patient with probable Alzheimer’s disease).

The proportion of cells producing IL-1α was approximately 25% higher in patients with probable diagnosis of the disease as compared to those cognitively intact (Table 4). In the case of IL-6 and TNF-α, there were no statistically significant differences in the proportion of cells that produced those interleukins (Figure 2 and Table 4).

Figure 2: Representative flow cytometric detection of monocyte intracellular production of IL-1α, IL-6, and TNF-α. Monocytes were selected in a similar manner as described in Figure 1. LPS-induced production of each cytokine was determined by the percentage of events in the upper right quadrant (%URQ). Only upper quadrants are shown. INT (sample from cognitively intact patient) and AD (sample from patient with probable Alzheimer’s disease).

The oxidative metabolism of monocytes studied with flow cytometry techniques showed no differences between groups (Table 4).

4. Discussion

The aim of this study was to investigate the interrelationship between AD, blood parameters of oxidative stress, and indicators of inflammatory activity in monocytes. It follows the reasoning by which monocytes are circulating cells that resemble the brain microglia and may even be recruited from blood to brain tissue [15] in AD. Microglia are considered the main element for the localized inflammatory events that accompany this disease [16]. This would lead to localized inflammation and increased production of reactive oxygen species, causing oxidative stress, which could be reflected by circulating parameters [17].

In the conditions of this work, AD is not associated with any evidence of systemic oxidative stress. Although the activities of erythrocyte antioxidant enzymes do not show changes in patients with AD, Spearman rank correlation test reveals a positive correlation between the mutual activities of erythrocyte superoxide dismutase, catalase, and glutathione peroxidase and erythrocyte total glutathione levels. These data confirm the validity of the postulate that says that the body’s antioxidant systems act together in an integrated manner. Spearman test has also identified a negative correlation between the levels of lipid peroxidation products, plasma glutathione peroxidase activity, and total glutathione levels in erythrocytes. This fact indicates that lipid peroxidation is influenced by the activity of antioxidant glutathione peroxidase-glutathione system in this experimental model. Indeed, glutathione-glutathione peroxidase system is an important component of antioxidant protection network to cells [18]. As a counterpoint to the measurement of erythrocyte antioxidant activities, circulating levels of oxidation products of macromolecules in the body have been evaluated. To this end, we analyzed levels of plasma protein carbonyls and plasma levels of lipid peroxidation products. Plasma level of protein oxidation products is not altered in AD compared with cognitively intact group. This lack of change is found in some studies [18]. On the other hand, some authors have found an increase of oxidized proteins in plasma from AD patients [19, 20]. This difference may be due to difference of sensitivity of the methods employed in the mentioned studies (two-dimensional electrophoresis, mass spectrometry) in relation to enzyme-immunoassay method chosen for this work and the possible differences in quality of care and feeding among the target populations of each study. Concentration of circulating lipid peroxidation products is equivalent in both groups, results that agree with those commonly found in the literature [18]. In general, the population studied seems to enjoy a privileged status in relation to nutritional populations examined in similar studies in other locations. In addition to the antioxidant profile outlined above, measurements of plasma levels of nonenzymatic antioxidants of low molecular weight were also carried out.

Values of vitamin C, β-carotene, and α-tocopherol, obtained in this study are within the range previously described for a healthy population group in that age [7, 21]. A review of several published papers, performed by Stocker and Frei [22], shows populational values for plasma concentrations of vitamin C, α-tocopherol, and β-carotene ranging from 30 to 150 μM, 15 to 40 μM, and 0.3 to 0.6 μM, respectively. Other authors report that, for cardiovascular disease and cancer prevention, concentrations above 30 μM α-tocopherol in combination with concentrations greater than 50 μM of vitamin C, 0.4 μM β-carotene, and 0.5 μM lycopene are desired [23]. Thus, the two groups of elderly patients studied have positioned themselves within the limits found in several other studies to molecular plasma levels of antioxidants. These parameters reflect part of the antioxidant defense system of the body of patients, evaluating components that can be absorbed directly from the diet, so further promoted by the antioxidant defense mentioned above. Of all low molecular weight antioxidants studied, only vitamin E significantly differs between groups. The INT group has levels of plasma vitamin E higher than those in AD patients.

This apparent homogeneity in antioxidant levels between the various groups opposed to other studies in the literature [2427]. This finding, as previously mentioned, reinforces the notion that the oxidative processes that are triggered during the course of AD are not always reflected in circulating blood, and even when that occurs, it may be only an indication of other underlying mechanisms. Of special interest is the fact that the establishment of AD, expressed by the comparison between the INT and AD groups in our study, is accompanied by the decrease of circulating vitamin E, which possesses antioxidant capabilities as well as recognized anti-inflammatory activities due to its action on signal transduction mechanisms in phagocytes [28, 29]. Not surprisingly, studies that have obtained the best results in preventing or treating AD in recent years used α-tocopherol as an agent [30].

To complete the picture outlined up to this point, circulating monocytes were analyzed by flow cytometry as indicators of inflammatory activity involved in AD. To this end, we quantified the level of expression of surface molecules HLA-DR, as an indicator of activation of circulating monocytes, and CD-11b, an adhesion molecule involved in the process of marginalization and migration of monocytes. The results show that AD patients have circulating monocytes that express higher amounts of HLA-DR on the surface even without external stimulus, indicating a higher basal activation state of these cells, confirming the data available in the literature [31]. Markers of increased activation of monocytes in the bloodstream are found in patients from a number of neurodegenerative diseases [32]. As previously mentioned, these circulating monocytes can cross the blood-brain barrier and migrate to the brain tissue, differentiating into microglia. Since circulating monocytes of AD patients are more active at baseline than those of INT, it can be postulated that microglia derived from these cells react more intensely to inflammatory stimuli, producing greater injury to brain. Level of expression of surface protein CD-11b is the same in both groups indicating that the potential for adhesion and migration of these cells is not altered in this pathology.

Also by flow cytometry, monocytes production of IL-1α, IL-6, and TNF-α was measured. This measurement was intended to evaluate the capacity of circulating monocytes to stimulate the inflammatory process by attracting new monocytes to the inflammatory site. The production of IL-1α is higher in monocytes from AD patients than in INT group. Since IL-1α is an important proinflammatory cytokine, it is plausible to assume that migration and differentiation of these monocytes produce more active microglia. This increased production of IL-1α was shown in vitro in human monocytes lineage, when stimulated by PβA, by means of mechanisms of signal transduction mediated by tyrosine kinases, which reinforces the above hypothesis [33].

Levels of IL-6 produced by stimulated peripheral monocytes are similar in both groups, as well as of TNF-α, agreeing with Beloosesky et al. [34]. Other authors detected an increase in IL-6 production by monocytes of AD patients [35] using, however, a different stimulus (phytohemagglutinin) than that used in this present study (LPS).

From the data shown here, it is reasonable to conclude that AD is accompanied by the activation of circulating monocytes and a decrease in circulating levels of vitamin E. Several studies show α-tocopherol modulating inflammation activity [28, 36]. In our study, the group of patients, where plasma α-tocopherol is decreased, also showed more activated monocytes that respond to stimuli with an increased production of proinflammatory cytokine IL-1α. This study points out that AD is associated with a higher basal activation of circulating monocytes that may be a result of α-tocopherol stock depletion.


AD:Alzheimer’s disease
CDR:Clinical dementia rating
FITC:Fluorescein isothiocyanate
INT:Cognitively intact group
GMFI:Geometric mean fluorescence intensity
MMSE:Minimental state examination
PerCP:Periidinin chlorophyll protein
ROS:Reactive oxygen species
URQ:Upper right quadrant.


  1. B. C. Dickerson, A. Bakkour, D. H. Salat et al., “The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals,” Cerebral Cortex, vol. 19, no. 3, pp. 497–510, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Jana and K. Pahan, “Fibrillar amyloid-β peptides kill human primary neurons via NADPH oxidase-mediated activation of neutral sphingomyelinase: Implications for Alzheimer's disease,” Journal of Biological Chemistry, vol. 279, no. 49, pp. 51451–51459, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. C. E. Finch and T. E. Morgan, “Inflammatory processes of Alzheimer disease and aging,” Proceedings of the Indian National Science Academy B, vol. 69, pp. 165–178, 2003. View at Google Scholar
  4. E. Zotova, J. A. Nicoll, R. Kalaria, C. Holmes, and D. Boche, “Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy,” Alzheimer's Research and Therapy, vol. 2, no. 1, article 1, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. L. E. Rojo, J. A. Fernández, A. A. Maccioni, J. M. Jimenez, and R. B. Maccioni, “Neuroinflammation: implications for the pathogenesis and molecular diagnosis of Alzheimer's disease,” Archives of Medical Research, vol. 39, no. 1, pp. 1–16, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. K. Jomova, D. Vondrakova, M. Lawson, and M. Valko, “Metals, oxidative stress and neurodegenerative disorders,” Molecular and Cellular Biochemistry, vol. 345, no. 1-2, pp. 91–104, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. V. B. C. Junqueira, S. B. M. Barros, S. S. Chan et al., “Aging and oxidative stress,” Molecular Aspects of Medicine, vol. 25, no. 1-2, pp. 5–16, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini-mental state A practical method for grading the cognitive state of patients for the clinician,” Journal of Psychiatric Research, vol. 12, no. 3, pp. 189–198, 1975. View at Publisher · View at Google Scholar
  9. J. C. Morris, “The Clinical Dementia Rating (CDR): current version and scoring rules,” Neurology, vol. 43, no. 11, pp. 2412–2414, 1993. View at Google Scholar · View at Scopus
  10. M. B. M. Montaño and L. R. Ramos, “Validity of the Portuguese version of Clinical Dementia Rating,” Revista de Saúde Pública, vol. 39, no. 6, pp. 912–917, 2005. View at Google Scholar
  11. F. Tietze, “Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues,” Analytical Biochemistry, vol. 27, no. 3, pp. 502–522, 1969. View at Google Scholar · View at Scopus
  12. H. Buss, T. P. Chan, K. B. Sluis, N. B. Domigan, and C. C. Winterbourn, “Protein carbonyl measurement by a sensitive ELISA method,” Free Radical Biology and Medicine, vol. 23, no. 3, pp. 361–366, 1998. View at Publisher · View at Google Scholar
  13. M. K. C. Brunialti, E. G. Kallás, M. Freudenberg, C. Galanos, and R. Salomão, “Influence of EDTA and heparin on lipopolysaccharide binding and cell activation, evaluated at single-cell level in whole blood,” Clinical Cytometry, vol. 50, no. 1, pp. 14–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Hasui, Y. Hirabayashi, and Y. Kobayashi, “Simultaneous measurement by flow cytometry of phagocytosis and hydrogen peroxide production of neutrophils in whole blood,” Journal of Immunological Methods, vol. 117, no. 1, pp. 53–58, 1989. View at Publisher · View at Google Scholar · View at Scopus
  15. J. Wegiel, H. Imaki, K.-C. Wang et al., “Origin and turnover of microglial cells in fibrillar plaques of APPsw transgenic mice,” Acta Neuropathologica, vol. 105, no. 4, pp. 393–402, 2003. View at Google Scholar · View at Scopus
  16. M. R. D'Andrea, G. M. Cole, and M. D. Ard, “The microglial phagocytic role with specific plaque types in the Alzheimer disease brain,” Neurobiology of Aging, vol. 25, no. 5, pp. 675–683, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Viña, A. Lloret, R. Ortí, and D. Alonso, “Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress,” Molecular Aspects of Medicine, vol. 25, no. 1-2, pp. 117–123, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. M. C. Polidori, P. Mattioli, S. Aldred et al., “Plasma antioxidant status, immunoglobulin G oxidation and lipid peroxidation in demented patients: relevance to Alzheimer disease and vascular dementia,” Dementia and Geriatric Cognitive Disorders, vol. 18, no. 3-4, pp. 265–270, 2004. View at Publisher · View at Google Scholar · View at Scopus
  19. C. C. Conrad, P. L. Marshall, J. M. Talent, C. A. Malakowsky, J. Choi, and R. W. Gracy, “Oxidized proteins in Alzheimer's plasma,” Biochemical and Biophysical Research Communications, vol. 275, no. 2, pp. 678–681, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Choi, C. A. Malakowsky, J. M. Talent, C. C. Conrad, and R. W. Gracy, “Identification of oxidized plasma proteins in Alzheimer's disease,” Biochemical and Biophysical Research Communications, vol. 293, no. 5, pp. 1566–1570, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. H. Heseker and R. Schneider, “Requirement and supply of vitamin C, E and β-carotene for elderly men and women,” European Journal of Clinical Nutrition, vol. 48, no. 2, pp. 118–127, 1994. View at Google Scholar · View at Scopus
  22. R. Stocker and B. Frei, “Endogenous antioxidant defences in human blood plasma,” in Oxidative Stress: Oxidants and Antioxidants, H. Sies, Ed., Academic Press, London, UK, 1991. View at Google Scholar
  23. K. F. Gey, “Prevention of early stages of cardiovascular disease and cancer may require concurrent optimization of all major antioxidants and other nutrients, an update and reevaluation of observational data and intervention trials,” in Free Radicals, Lipoprotein Oxidation and Atherosclerosis, C. Rice-Evans, Ed., Richelieu Press, London, UK, 1995. View at Google Scholar
  24. C. Behl and B. Moosmann, “Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach,” Free Radical Biology and Medicine, vol. 33, no. 2, pp. 182–191, 2002. View at Publisher · View at Google Scholar · View at Scopus
  25. E. Esposito, D. Rotilio, V. di Matteo, C. di Giulio, M. Cacchio, and S. Algeri, “A review of specific dietary antioxidants and the effects on biochemical mechanisms related to neurodegenerative processes,” Neurobiology of Aging, vol. 23, no. 5, pp. 719–735, 2002. View at Publisher · View at Google Scholar · View at Scopus
  26. P. Mecocci, M. Cristina Polidori, A. Cherubini et al., “Lymphocyte oxidative DNA damage and plasma antioxidants in Alzheimer disease,” Archives of Neurology, vol. 59, no. 5, pp. 794–798, 2002. View at Google Scholar · View at Scopus
  27. M. Sano, “Do dietary antioxidants prevent Alzheimer's disease?” The Lancet Neurology, vol. 1, no. 6, p. 342, 2002. View at Google Scholar · View at Scopus
  28. S. S. Chan, H. P. Monteiro, F. Schindler, A. Stern, and V. B. C. Junqueira, “α-tocopherol modulates tyrosine phosphorylation in human neutrophils by inhibition of protein kinas C activity and activation of tyrosine phosphatases,” Free Radical Research, vol. 35, no. 6, pp. 843–856, 2001. View at Google Scholar · View at Scopus
  29. E. M. Bulger and R. V. Maier, “An argument for vitamin E supplementation in the management of systemic inflammatory response syndrome,” Shock, vol. 19, no. 2, pp. 99–103, 2003. View at Google Scholar · View at Scopus
  30. P. P. Zandi, J. C. Anthony, A. S. Khachaturian et al., “Reduced risk of Alzheimer disease in users of antioxidant vitamin supplements: the Cache County study,” Archives of Neurology, vol. 61, no. 1, pp. 82–88, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Kusdra, H. Rempel, K. Yaffe, and L. Pulliam, “Elevation of CD69+ monocyte/macrophages in patients with Alzheimer's disease,” Immunobiology, vol. 202, no. 1, pp. 26–33, 2000. View at Google Scholar · View at Scopus
  32. J. A. Casal, A. Robles, and J. C. Tutor, “Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia,” Clinical Biochemistry, vol. 36, no. 7, pp. 553–556, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. C. K. Combs, J. Colleen Karlo, S.-C. Kao, and G. E. Landreth, “β-amyloid stimulation of microglia anti monocytes results in TNFα-dependent expression of inducible nitric oxide synthase and neuronal apoptosis,” Journal of Neuroscience, vol. 21, no. 4, pp. 1179–1188, 2001. View at Google Scholar · View at Scopus
  34. Y. Beloosesky, H. Salman, M. Bergman, H. Bessler, and M. Djaldetti, “Cytokine levels and phagocytic activity in patients with Alzheimer's disease,” Gerontology, vol. 48, no. 3, pp. 128–132, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. F. Shalit, B. Sredni, L. Stern, E. Kott, and M. Huberman, “Elevated interleukin-6 secretion levels by mononuclear cells of Alzheimer's patients,” Neuroscience Letters, vol. 174, no. 2, pp. 130–132, 1994. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Azzi, R. Gysin, P. Kempná et al., “The role of α-tocopherol in preventing disease: from epidemiology to molecular events,” Molecular Aspects of Medicine, vol. 24, no. 6, pp. 325–336, 2003. View at Publisher · View at Google Scholar · View at Scopus